Clinical Trials Logo

Clinical Trial Summary

The goal of this study is to determine the impact of apheresis on clinical parameters and symptoms of patients with refractory angina and raised Lp(a). The investigators will conduct a prospective, randomised controlled crossover study of 20 patients with refractory angina and raised Lp(a), randomised to undergoing lipoprotein apheresis weekly for three months or sham apheresis weekly for three months with assessment of myocardial perfusion, carotid atherosclerosis, endothelial vascular function, thrombogenesis, exercise capacity, angina symptoms and quality of life at the beginning and end of treatment. Patients will then crossover to the opposite study arm with the protocol repeated. The hypothesis is that the above parameters will be improved by lipoprotein apheresis in patients with raised Lp(a) and Refractory Angina. Investigators will also test for the genotypic presence of apolipoprotein(a) gene (LPA) locus variants (rs10455872 and rs3798220) which are thought to be associated with an increased level of Lp(a) and an increased risk of coronary disease.


Clinical Trial Description

Angina which is refractory to conventional medical therapy and revascularisation is challenging to manage. Lipoprotein(a) or Lp(a) is a genetically determined form of LDL-cholesterol, elevation of which is an independent risk factor and predictor of adverse cardiovascular events. Lp(a) is felt to increase cardiovascular risk via its prothrombotic effect and by enhancing intimal lipoprotein deposition. Lipoprotein apheresis is the most effective treatment for raised Lp(a). Lipid lowering agents such as statins have little to no effect on Lp(a) levels. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01796912
Study type Interventional
Source Imperial College London
Contact
Status Completed
Phase N/A
Start date February 2013
Completion date November 2015

See also
  Status Clinical Trial Phase
Completed NCT01205893 - Coronary Sinus Reducer for Treatment of Refractory Angina - COSIRA Phase 2
Not yet recruiting NCT05711849 - Assessing the Safety and Effectiveness of Intracoronary Stem Cells in Patients With Refractory Angina Phase 2
Suspended NCT04306237 - A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Refractory Angina Phase 2
Recruiting NCT04892537 - Coronary Sinus Reducer Objective Impact on Symptoms, MRI Ischaemia and Microvascular Resistance N/A
Completed NCT00694642 - Safety and Efficacy of Autologous Endothelial Progenitor Cell CD 133 for Therapeutic Angiogenesis Phase 1/Phase 2
Suspended NCT00820586 - Intramyocardial Delivery of Autologous Bone Marrow Phase 2
Recruiting NCT04368819 - Allopurinol in Patients With Refractory Angina to Improve Ischemic Symptoms Phase 2/Phase 3
Recruiting NCT03455725 - CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial N/A
Completed NCT01966042 - Study Protocol of Intramyocardial Injection of Autologous Bone Marrow Stem Cells for Refractory Angina Phase 2
Recruiting NCT03991871 - HARapan kiTa ECP (External Counter Pulsation) Study HARTEC Study N/A
Recruiting NCT05102019 - Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II N/A
Completed NCT03218891 - Cardiac Rehabilitation in Patients With Refractory Angina N/A
Completed NCT03350737 - Coronary Arteriogenetic Heparinized Exercise N/A
Recruiting NCT01566175 - Use of the Neovasc Coronary Sinus Reducer System for the Treatment of Refractory Angina Pectoris in Patients With Ngina Class 3-4 Who Are Not Candidates for Revascularization N/A
Recruiting NCT05492110 - Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microvascular Dysfunction. N/A
Recruiting NCT04606459 - COSIMA: COronary SInus Reducer for the Treatment of Refractory Microvascular Angina N/A